Drugs / S095024
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06162572 | Aug 2024 → Apr 2027 expected | non-small cell lung carcinoma | Servier Bio-Innovation LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S095024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06162572 ↗ |
| Route | Intravenous | “Via IV infusion on Day 1 of each 21-day cycle” NCT06162572 ↗ |